Telo Genomics Corp (TELO) AI Stock Analysis

• Market Cap: C$9.98M
• Dividend Yield: N/A
• Average Volume (3M): 14.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 28.89%
• Country: CA
• Employees: 8
• Sector: Technology
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 99,811,180
• 10 Day Avg. Volume: 27,650
• 30 Day Avg. Volume: 14,680
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -6.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Telo Genomics Corp currently presents a high-risk investment profile, primarily due to its significant financial challenges, including no revenue generation and persistent losses. Despite a strong equity position and positive recent corporate developments, the bearish technical indicators and negative valuation metrics weigh heavily on the stock's attractiveness. If strategic initiatives succeed, there could be potential upside, but the current risks are substantial.

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp (TELO) is a biotechnology company specializing in the development and commercialization of innovative genetic testing services. Operating primarily in the healthcare sector, Telo Genomics focuses on leveraging its proprietary technology, TeloView, to provide advanced genomic solutions that assist in the management and treatment of cancer and other diseases. The company's core offerings include diagnostic and prognostic tests designed to enhance patient care through early detection and personalized medicine.

How the Company Makes Money

Telo Genomics Corp generates revenue by offering its proprietary genomic testing services to healthcare providers, research institutions, and pharmaceutical companies. Key revenue streams include fees charged for conducting diagnostic and prognostic tests using the TeloView platform. The company may also engage in collaborative partnerships and licensing agreements to further monetize its technology. These partnerships potentially involve sharing its genomic data insights with pharmaceutical companies for drug development and clinical research purposes. Additionally, Telo Genomics may receive grants or funding from governmental or private organizations that support innovation in healthcare technology.

Telo Genomics Corp Financial Statement Overview

Summary

Telo Genomics Corp is facing significant financial challenges, with no revenue generation and persistent losses. While the company benefits from a strong equity base and no debt, the lack of revenue growth and negative cash flows raise concerns about its long-term viability. Continued reliance on external financing is unsustainable without improvements in operational performance.

Income Statement

The income statement shows significant challenges, with zero revenue and persistent net losses over the years. Margins such as the gross profit margin and net profit margin are undefined due to the absence of revenue. The company has not demonstrated revenue growth, which is crucial for future sustainability.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, leading to a favorable debt-to-equity ratio. However, equity has been decreasing over time. The equity ratio is relatively high, indicating financial stability despite ongoing losses. The absence of liabilities suggests low risk in terms of financial obligations.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, reflecting operational challenges. While the operating cash flow remains negative, indicating inefficiencies, the company has been able to secure financing, which temporarily bolsters cash reserves. However, the lack of revenue generation continues to be a major concern.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-18.68K	-39.54K	-33.11K	-56.96K	-62.23K	-64.72K
	EBIT
-1.21M	-2.72M	-2.82M	-2.11M	-1.07M	-1.22M
	EBITDA
-2.35M	-2.67M	-2.78M	-2.05M	-1.01M	-1.15M
	Net Income Common Stockholders
-2.37M	-2.71M	-2.82M	-2.11M	-1.07M	-1.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.25M	796.02K	2.67M	2.69M	3.64M	920.98K
	Total Assets
2.35M	965.64K	2.93M	2.83M	3.84M	1.17M
	Total Debt
0.00	0.00	32.50K	40.00K	40.00K	40.00K
	Net Debt
-2.25M	-796.02K	-2.64M	-2.65M	-3.60M	-880.98K
	Total Liabilities
603.77K	375.59K	312.87K	230.07K	153.66K	393.42K
	Stockholders Equity
1.75M	590.06K	2.61M	2.60M	3.69M	775.25K
Cash Flow		Free Cash Flow
-1.96M	-2.46M	-2.70M	-1.82M	-1.11M	-1.13M
	Operating Cash Flow
-1.96M	-2.46M	-2.63M	-1.79M	-1.10M	-1.12M
	Investing Cash Flow
-2.31K	-5.12K	-69.06K	-25.19K	-9.31K	-8.67K
	Financing Cash Flow
2.92M	587.05K	2.68M	876.65K	3.83M	2.03M

Telo Genomics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	67 Neutral	C$350.07M	―	-3.15%	4.78%	-15.41%	-69.47%
Sector *	57 Neutral	$20.24B	9.51	-13.28%	2.72%	5.43%	-24.54%
EXRO	44 Neutral	$41.22M	―	-1039.46%	―	322.75%	-93.21%
TELO	27 Underperform	C$9.98M	―	-160.60%	―	―	28.89%

Telo Genomics Corp Corporate Events

Telo Genomics’ MRD Data in Multiple Myeloma Gains ASCO Recognition

Telo Genomics Corp announced the acceptance of its abstract on Minimal Residual Disease (MRD) validation data in multiple myeloma by the American Society of Clinical Oncology (ASCO) for online publication at their 2025 Annual Meeting. This recognition underscores the significance of Telo’s TeloView® technology in assessing MRD, which is crucial for monitoring myeloma post-transplantation. The company’s ongoing clinical trials aim to develop prognostic tests that could revolutionize precision medicine by providing actionable insights for clinicians. The acceptance by ASCO, a prestigious oncology conference, highlights the potential impact of Telo’s innovations on the treatment and management of multiple myeloma, a challenging blood cancer.

Spark’s Take on TSE:TELO Stock

According to Spark, TipRanks’ AI Analyst, TSE:TELO is a Underperform.

Telo Genomics Corp faces substantial financial challenges, with no revenue and persistent losses being significant risks. The technical analysis indicates a bearish trend, while the negative P/E ratio underscores valuation concerns. Recent corporate events provide some optimism for future operational improvements, but these have yet to translate into financial stability. Overall, the stock is high-risk, with potential upside if strategic initiatives succeed.

To see Spark’s full report on TSE:TELO stock, click here.

Telo Genomics Strengthens Leadership with New Board Appointment

Telo Genomics Corp. has appointed John Farlinger to its Board of Directors, where he will also serve as Chair of the audit committee. Farlinger brings over 30 years of experience in telecom, operations, technology, and finance, which is expected to bolster Telo Genomics’ strategic leadership and support its growth phase. Additionally, the company has granted stock options to Farlinger and a strategic consultant, reflecting its commitment to aligning incentives with its development goals. This move is anticipated to enhance Telo Genomics’ operational capabilities and strengthen its market position in the biotech industry.

Telo Genomics Strengthens Leadership with New Executive Chairman

Telo Genomics Corp has appointed Guido Baechler as the Executive Chairman of its Board of Directors, enhancing his role to provide strategic leadership in advancing the company’s machine-learning-driven 3D Telomere platform in oncology. This move is expected to support the company’s growth and commercialization efforts, particularly in the areas of multiple myeloma and prostate cancer. The company also announced stock option grants to insiders, employees, and consultants, and reported changes in its board and management team.

Telo Genomics Expands Partnership with Trusted Health Advisors for Diagnostic Advancements

Telo Genomics Corp has expanded its partnership with Trusted Health Advisors to enhance the commercialization of its diagnostic technologies over a six-month period. This collaboration will support various clinical programs, including those targeting multiple myeloma and prostate cancer, and involves the establishment of a clinical advisory board and collaboration with academic partners and reference labs. The partnership aims to advance Telo’s market positioning in oncology diagnostics by leveraging the expertise of THA’s experienced team.